Peregrine wins $44M contract; Halozyme touts data;

> Peregrine Pharmaceuticals has won a $44 million Department of Defense contract to test Bavituximab as a therapy for viral hemorrhagic fever infections. Story

> Halozyme says that Chemophase met its primary endpoint in a continuing Phase I/IIa trial for superficial bladder cancer. Report

> Adventrx Pharmaceuticals announced preliminary response rate results from its discontinued Phase II clinical trial of ANX-510, or CoFactor, its folate-based biomodulator of 5-FU for metastatic colorectal cancer. Adventrx release

> AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. and trade on the London exchange. Report

> Alabama stuck an $800 million suggested price on its Medicaid fraud case against GlaxoSmithKline and Novartis. Fraud report

> Avastin may have lost its chance to go on the U.K.'s National Health Service formulary, but it's still blowing past sales expectations. Avastin report

> What's a surefire way to win a contest? Keep your opponent from showing up, of course. That's what GlaxoSmithKline is trying to do in the over-the-counter weight-loss market. Report

> It's a watershed moment: Risperdal has gone generic. The Johnson & Johnson antipsychotic med now has copycat competition from Teva Pharmaceutical, which got the final FDA go-ahead yesterday. Risperdal report

> Sangamo BioSciences has reported new work in Nature Biotechnology demonstrating the effectiveness of its zinc finger DNA-binding proteins in immunizing cells in the immune system against HIV. Sangamo report

> The drumbeat of criticism over the impact of flat-line budgets at the NIH on the U.S. research community continues to build. In a recent article for the Star-Ledger, scientists report that original grant funding for projects dropped from 30 percent in 1999 to 12 percent today. Report

Industry Voices: Personalized medicine will drive management and restrictions by health plans. Report

And Finally... Researchers say that caffeine could prove an effective tool to prevent MS. Article

Suggested Articles

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.